A Phase 1b/2, Open Label, Dose Finding Study To Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Either Crizotinib Or Pf 06463922 In Patients With Advanced Or Metastatic Non Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Avelumab (Primary) ; Crizotinib; Lorlatinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Javelin Lung 101
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Planned End Date changed from 13 Jan 2018 to 14 Jan 2018.
- 06 Jun 2017 Planned primary completion date changed from 13 Jan 2018 to 14 Jan 2018.